Загрузка...
Current state of immunotherapy for non-small cell lung cancer
Lung cancer is the leading cause of cancer mortality and non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancers. Platinum-based doublet chemotherapy is the standard first-line treatment for metastatic NSCLC when genomic testing reveals no targetable alteration such as epid...
Сохранить в:
| Опубликовано в: : | Transl Lung Cancer Res |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
AME Publishing Company
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5420529/ https://ncbi.nlm.nih.gov/pubmed/28529902 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2017.03.01 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|